Brought to you by 
Sosei licenses Atrix's Eligard in Japan
04 Aug 2003
Executive Summary
Sosei Co. (oncology and urology drugs) licensed exclusive Japanese rights to Atrix Laboratories' (drug delivery) Eligard (leuprolide acetate), which is indicated for prostate cancer.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sosei licenses Atrix's Eligard in Japan
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice